BrightGene Bio-Medical Technology Gets Ethics Approval for Phase 3 Trial for Blood Sugar Injection

MT NewswiresDec 5, 2024 04:49 ET

Is BrightGene Bio-Medical Technology (SHSE:688166) A Risky Investment?

Simply Wall StNov 29, 2024 19:39 ET

BrightGene Bio-Medical Technology's (SHSE:688166) Earnings Have Declined Over Three Years, Contributing to Shareholders 13% Loss

Simply Wall StNov 8, 2024 20:10 ET

The Recent 4.6% Gain Must Have Brightened CEO Jiandong Yuan's Week, BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) Most Bullish Insider

Simply Wall StOct 21, 2024 22:55 ET

BrightGene Bio-Medical Technology Completes Phase II Clinical Trial for Weight Loss Drug

MT NewswiresOct 14, 2024 04:41 ET

Optimistic Investors Push BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shares Up 28% But Growth Is Lacking

Simply Wall StSep 30, 2024 21:19 ET